Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key

Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key

A combination of tyrosine kinase inhibitors (TKIs) is likely to be a therapeutic option for numerous oncological situations due to high frequency of oncogenic addiction and progress in precision oncology. Non-small cell lung cancer (NSCLC) represents a subtype of tumors for which oncogenic drivers a...

Full description

Bibliographic Details
Main Authors: Quentin Dominique Thomas, Nelly Firmin, Litaty Mbatchi, Alexandre Evrard, Xavier Quantin, Fanny Leenhardt
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:International Journal of Molecular Sciences
Subjects:
lung cancer
gastrointestinal stromal tumor (GIST)
osimertinib
crizotinib
imatinib
tyrosine kinase inhibitor
Online Access:https://www.mdpi.com/1422-0067/24/6/5518

Internet

https://www.mdpi.com/1422-0067/24/6/5518

Similar Items